


PHARMACEUTICAL 2021

Minerva Neurosciences Inc. Rank 10 of 409







PHARMACEUTICAL 2021



RealRate

Minerva Neurosciences Inc. Rank 10 of 409

The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 511% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 4.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 210%, being 565% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	27,440
Cost of Goods Sold	0
Intangible Assets	30,069
Liabilities, Current	3,160
Liabilities, Non-Current	0
Other Assets	117
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,803
Other Net Income	94
Property and Equipment	0
Research and Development	22,039
Revenues	41,176
Selling, General and Administrative Expense	17,289

Output Variable	Value in 1000 USD
Assets	57,626
Liabilities	4,964
Expenses	39,329
Stockholders Equity	52,663
Net Income	1,941
Comprehensive Net Income	1,941
Economic Capital Ratio	210%

